Obinutuzumab cycloPHOSphamide vinCRIStine and prednisoLONE (O-CVP) Therapy - 21 day. NCCP National SACT Regimen. HSE.
Regulatory approval published by the Health Service Executive.
Citation
Regulatory approvals
Approved indications from this document for cancer drugs containing at least one biomarker.
| Indication | Statements |
|---|---|
| Obinutuzumab in combination with CVP chemotherapy is indicated for the treatment of patients with previously untreated advanced follicular lymphoma. | 1 |
Therapeutic response
Precision oncology relationships for therapeutic response derived from this document.
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| HSE (1) | CD20 + | Follicular Lymphoma | Cyclophosphamide, Obinutuzumab, Prednisolone, Vincristine |